{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:12:12Z","timestamp":1767136332099,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd013653","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000}}],"reference-count":116,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013653.pub2","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T08:19:15Z","timestamp":1686557955000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus"],"prefix":"10.1002","volume":"2023","author":[{"given":"Emmanuel O","family":"Ugwu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology; Faculty of Medical Sciences, College of Medicine, University of Nigeria Nsukka\/University of Nigeria Teaching Hospital Ituku-Ozalla, Enugu State; Enugu Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George U","family":"Eleje","sequence":"additional","affiliation":[{"name":"Effective Care Research Unit, Department of Obstetrics and Gynaecology; Faculty of Medicine, College of Health Sciences, Nnamdi Azikiwe University, Nnewi Campus; PMB 5001, Nnewi Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela O","family":"Ugwu","sequence":"additional","affiliation":[{"name":"Department of Haematology and Immunolology; College of Medicine, University of Nigeria Nsukka\/University of Nigeria Teaching Hospital Ituku Ozalla, Enugu State; Enugu Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uchenna I","family":"Nwagha","sequence":"additional","affiliation":[{"name":"Department of Haematology and Immunology; Faculty of Medical Sciences, College of Medicine, University of Nigeria Nsukka\/University of Nigeria Teaching Hospital Ituku-Ozalla, Enugu State; Enugu Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph I","family":"Ikechebelu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology; Nnamdi Azikiwe University Teaching Hospital; Nnewi Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uchenna A","family":"Umeh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology; Faculty of Medical Science, College of Medicine, University of Nigeria Enugu Campus\/University of Nigeria Teaching Hospital Ituku-Ozalla, Enugu State; Enugu Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrietta U","family":"Okafor","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; Faculty of Medical Sciences, College of Medicine, University of Nigeria Enugu Campus\/University of Nigeria Teaching Hospital Ituku-Ozalla, Enugu State; Enugu Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"issue":"S1","key":"10.1002\/14651858.CD013653.pub2-BIB0001|cit1","first-page":"494A","article-title":"Safety and HBV efficacy of antiretroviral therapy in women with HIV and HBV in the promoting maternal and infant survival everywhere study (PROMISE)","volume":"72","author":"Bhattacharya","year":"2020","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0002|cit2","unstructured":"Fowler MG Pinilla M Dadabhai S Owor M Stranix-Chibanda L Flynn P Preterm birth, breastfeeding, antenatal ARV regimen and 24-month HIV-free survival www.impaactnetwork.org\/sites\/default\/files\/inline-files\/PROMISE_Fowler_CROI2021_ScienceSpotlight_InfantHIVsurvival_0.pdf"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/QAI.0000000000003022","article-title":"Brief Report: Impact of antiretroviral regimen on pregnancy and infant outcomes in women with HIV\/HBV coinfection.","volume":"91","author":"Kiweewa","year":"2022","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"11","key":"10.1002\/14651858.CD013653.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1097\/INF.0000000000002152","article-title":"Tenofovir disoproxil fumarate use during pregnancy and infant bone health: the Tenofovir in Pregnancy Pilot Study","volume":"37","author":"Kourtis","year":"2018","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"11","key":"10.1002\/14651858.CD013653.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/infdis\/jiw439","article-title":"Hepatitis B virus (HBV) load response to 2 antiviral regimens, tenofovir\/lamivudine and lamivudine, in HIV\/ HBV-coinfected pregnant women in Guangxi, China: the Tenofovir in Pregnancy (TiP) Study","volume":"214","author":"Wang","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.31083\/j.ceog.2021.01.2240","article-title":"Tenofovir disoproxil fumarate for preventing mother-to-child transmission of hepatitis B: a literature review","volume":"48","author":"Baciu","year":"2021","journal-title":"Clinical and Experimental Obstetetrics & Gynecology"},{"issue":"2","key":"10.1002\/14651858.CD013653.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0000000000002980","article-title":"Maternal HBV viremia and association with adverse infant outcomes in women living with HIV and HBV","volume":"40","author":"Bhattacharya","year":"2021","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12939-020-01268-3","article-title":"Tenofovir for prevention of mother to child transmission of hepatitis B in migrant women in a resource-limited setting on the Thailand-Myanmar border: a commentary on challenges of implementation","volume":"19","author":"Bierhoff","year":"2020","journal-title":"International Journal for Equity In Health"},{"issue":"3","key":"10.1002\/14651858.CD013653.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jcph.1746","article-title":"Effect of pregnancy and concomitant antiretrovirals on the pharmacokinetics of tenofovir in women with HIV receiving tenofovir disoproxil fumarate-based antiretroviral therapy versus women with HBV receiving tenofovir disoproxil fumarate monotherapy","volume":"61","author":"Bukkems","year":"2021","journal-title":"Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD013653.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mSphere.00716-19","article-title":"Maternal humoral immune responses do not predict postnatal HIV-1 transmission risk in antiretroviral-treated mothers from the IMPAACT PROMISE Study","volume":"4","author":"Hompe","year":"2019","journal-title":"mSphere"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12879-016-1734-5","article-title":"Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen","volume":"16","author":"Jourdain","year":"2016","journal-title":"BMC Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD013653.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir versus placebo to prevent perinatal transmission of hepatitis B","volume":"378","author":"Jourdain","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"15514","DOI":"10.1038\/s41598-018-33833-w","article-title":"Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads","volume":"8","author":"Lin","year":"2018","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1002\/14651858.CD013653.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/hiv.12120","article-title":"Impact of maternal hepatitis B virus coinfection on mother-to-child transmission of HIV","volume":"15","author":"Mave","year":"2014","journal-title":"HIV Medicine"},{"issue":"24","key":"10.1002\/14651858.CD013653.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013653.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4103\/ijmm.IJMM_17_37","article-title":"Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy","volume":"36","author":"Sarkar","year":"2018","journal-title":"Indian Journal of Medical Microbiology"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0017|cit17","first-page":"35","article-title":"Investigational drugs with dual activity against HBV and HIV (review)","volume":"21","author":"Sun","year":"2021","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0018|cit18","unstructured":"American Association for the Study of Liver Diseases (AASLD) guidelines of 2018. Practice Guidelines www.aasld.org\/practice-guidelines"},{"issue":"9","key":"10.1002\/14651858.CD013653.pub2-BIB0019|cit19","first-page":"570","article-title":"Evaluation and management of hepatitis B in pregnancy: a survey of current practices","volume":"6","author":"Ahn","year":"2010","journal-title":"Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2334-14-180","article-title":"The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi","volume":"14","author":"Andreotti","year":"2014","journal-title":"BMC Infectious Diseases"},{"issue":"7454","key":"10.1002\/14651858.CD013653.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"GRADE Working Group. Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD013653.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.21106\/ijma.321","article-title":"Impact of highly active antiretroviral therapy on chronic hepatitis B serological markers among Senegalese HIV co-infected children","volume":"8","author":"Ba","year":"2019","journal-title":"International Journal of Maternal and Child Health and AIDS"},{"issue":"11","key":"10.1002\/14651858.CD013653.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1128\/AAC.05317-11","article-title":"Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients","volume":"55","author":"Baheti","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD013653.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000001618","article-title":"HBV or HCV coinfection in HIV-1-infected pregnant women in France: prevalence and pregnancy outcomes","volume":"77","author":"Benhammou","year":"2018","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"5","key":"10.1002\/14651858.CD013653.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.510300525","article-title":"Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3851\/IMP2972","article-title":"Tenofovir-based antiretroviral therapy in HBV-HIV coinfection: results from the TREAT Asia HIV Observational Database","volume":"21","author":"Boettiger","year":"2016","journal-title":"Antiviral Therapy"},{"issue":"7","key":"10.1002\/14651858.CD013653.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1017\/S0950268818000766","article-title":"HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities","volume":"146","author":"Bosh","year":"2018","journal-title":"Epidemiology and Infection"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.28302","article-title":"Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis","volume":"63","author":"McMahon","year":"2016","journal-title":"Hepatology"},{"issue":"22","key":"10.1002\/14651858.CD013653.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD013653.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/tpj.2015.71","article-title":"Clinical pharmacology of tenofovir clearance: a pharmacokinetic\/pharmacogenetic study on plasma and urine","volume":"16","author":"Calcagno","year":"2016","journal-title":"Pharmacogenomics Journal"},{"issue":"110","key":"10.1002\/14651858.CD013653.pub2-BIB0031|cit31","first-page":"1","article-title":"Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and Trial Sequential Analysis","volume":"7","author":"Castellini","year":"2018","journal-title":"Systematic Reviews 2018;7(110):1-10"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","author":"De Clercq","year":"2018","journal-title":"Biochemical Pharmacology"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch10"},{"issue":"4","key":"10.1002\/14651858.CD013653.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/aid.2017.0203","article-title":"Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment","volume":"34","author":"DeJesus","year":"2018","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"3","key":"10.1002\/14651858.CD013653.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"177\u201388","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1186\/s12913-019-4416-3","article-title":"Prevention and care of hepatitis B in the rural region of Fatick in Senegal: a healthcare workers' perspective using a mixed methods approach","volume":"19","author":"Djaogol","year":"2019","journal-title":"BMC Health Services Research"},{"issue":"7","key":"10.1002\/14651858.CD013653.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/380398","article-title":"Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus","volume":"189","author":"Dore","year":"2004","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013653.pub2-BIB0038|cit38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008545.pub2","article-title":"Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus","author":"Eke","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013653.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/17425255.2020.1738384","article-title":"Tenofovir alafenamide use in pregnant and lactating women living with HIV","volume":"16","author":"Eke","year":"2020","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"2","key":"10.1002\/14651858.CD013653.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4103\/2141-9248.129045","article-title":"Epidemiology and clinical parameters of adult human immunodeficiency virus\/acquired immunodeficiency syndrome at the initiation of antiretroviral therapy in South Eastern Nigeria","volume":"4","author":"Eleje","year":"2014","journal-title":"Annals of Medical and Health Sciences Research"},{"issue":"2","key":"10.1002\/14651858.CD013653.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/14767058.2017.1279600","article-title":"Mother-to-child transmission of human immunodeficiency virus (HIV) among HIV-infected pregnant women on highly active anti-retroviral therapy with premature rupture of membranes at term","volume":"31","author":"Eleje","year":"2018","journal-title":"Journal of Maternal-Fetal & Neonatal Medicine"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"251513552110325","DOI":"10.1177\/25151355211032595","article-title":"Pregnant women's hepatitis B vaccination coverage in Nigeria: a national pilot cross-sectional study","volume":"9","author":"Eleje","year":"2021","journal-title":"Therapeutic Advances in Vaccines and Immunotherapy"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"205031212210954","DOI":"10.1177\/20503121221095411","article-title":"Mother-to-child transmission of human immunodeficiency virus, hepatitis B virus and hepatitis C virus among pregnant women with single, dual or triplex infections of human immunodeficiency virus, hepatitis B virus and hepatitis C virus in Nigeria: a systematic review and meta-analysis","volume":"10","author":"Eleje","year":"2022","journal-title":"SAGE Open Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013653.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/15284336.2016.1276312","article-title":"HBV coinfection is associated with reduced CD4 response to antiretroviral treatment in pregnancy","volume":"18","author":"Floridia","year":"2017","journal-title":"HIV Clinical Trials"},{"issue":"18","key":"10.1002\/14651858.CD013653.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","article-title":"Benefits and risks of antiretroviral therapy for perinatal HIV prevention","volume":"375","author":"Fowler","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013653.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"e0219922","DOI":"10.1371\/journal.pone.0219922","article-title":"Hepatitis B and C infections in HIV-1 and non-HIV infected pregnant women in the Brong-Ahafo Region, Ghana","volume":"14","author":"Frempong","year":"2019","journal-title":"PLOS One"},{"issue":"3","key":"10.1002\/14651858.CD013653.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/QAI.0000000000001069","article-title":"Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide in HIV-1\/hepatitis B coinfected adults","volume":"73","author":"Gallant","year":"2016","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0048|cit48","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"10","key":"10.1002\/14651858.CD013653.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/hiv.12664","article-title":"Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials","volume":"19","author":"Hagins","year":"2018","journal-title":"HIV Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013653.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence","volume":"57","author":"Hall","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0051|cit51","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"issue":"6","key":"10.1002\/14651858.CD013653.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/319368","article-title":"Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens","volume":"32","author":"Hoff","year":"2001","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD013653.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1473-3099(07)70135-4","article-title":"Clinical implications of HIV and hepatitis B co-infection in Asia and Africa","volume":"7","author":"Hoffmann","year":"2007","journal-title":"Lancet Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013653.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/QAI.0000000000001193","article-title":"A randomized, open-label trial to evaluate switching to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1-infected adults","volume":"74","author":"Huhn","year":"2017","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0057|cit57","unstructured":"International Council for Harmonisation of technical requirements for pharmaceuticals for human use (ICH) ICH Harmonised Guideline. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2) database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"},{"issue":"8","key":"10.1002\/14651858.CD013653.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"e011890","DOI":"10.1136\/bmjopen-2016-011890","article-title":"False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review","volume":"6","author":"Imberger","year":"2016","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"12","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"10.1002\/14651858.CD013653.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/2042098613485276","article-title":"Is tenofovir\/emtricitabine teratogenic?","volume":"4","author":"Jibril","year":"2013","journal-title":"Therapeutic Advances in Drug Safety"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0061|cit61","first-page":"193","article-title":"HIV prevention cascade theory and its relation to social dimensions of health: a case for Nigeria","volume":"11","author":"Joe-Ikechebelu","year":"2019","journal-title":"HIV\/AIDS (Auckland, N.Z.)"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199936010-00004","article-title":"Clinical pharmacokinetics of lamivudine","volume":"36","author":"Johnson","year":"1999","journal-title":"Clinical Pharmacokinetics"},{"issue":"11","key":"10.1002\/14651858.CD013653.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD013653.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMp1201796","article-title":"HIV-HBV coinfection \u2013 a global challenge","volume":"366","author":"Kourtis","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Li C Yang Y Wang Y Dong S Yang Y Shi Y Impact of maternal HIV-HBV coinfection on pregnancy outcomes in an underdeveloped rural area of southwest China Sexually Transmitted Infections 2020 96 7 509 15 10.1136\/sextrans-2019-054295","DOI":"10.1136\/sextrans-2019-054295"},{"issue":"2","key":"10.1002\/14651858.CD013653.pub2-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12985-018-1050-3","article-title":"Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV\/HIV coinfection: a meta-analysis","volume":"15","author":"Luo","year":"2018","journal-title":"Virology Journal"},{"issue":"6","key":"10.1002\/14651858.CD013653.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/hiv.12120","article-title":"Impact of maternal hepatitis B virus coinfection on mother-to-child transmission of HIV","volume":"15","author":"Mave","year":"2014","journal-title":"HIV Medicine"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2458-10-105","article-title":"Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon","volume":"10","author":"Mbougua","year":"2010","journal-title":"BMC Public Health"},{"issue":"9128","key":"10.1002\/14651858.CD013653.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"609\u201313","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD013653.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48-week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fphar.2014.00248","article-title":"The role of drug transporters in the kidney: lessons from tenofovir","volume":"5","author":"Moss","year":"2014","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD013653.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"e0216293","DOI":"10.1371\/journal.pone.0216293","article-title":"Hepatitis B infection among pregnant and post-partum women living with HIV and on antiretroviral therapy in Kinshasa, DR Congo: a cross-sectional study","volume":"14","author":"Mpody","year":"2019","journal-title":"PLOS One"},{"issue":"4","key":"10.1002\/14651858.CD013653.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14656566.2020.1713096","article-title":"Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection","volume":"21","author":"Mu","year":"2020","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12879-018-3506-x","article-title":"Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis","volume":"18","author":"Naing","year":"2018","journal-title":"BMC Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD013653.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.52403\/ijhsr.20211201","article-title":"Outcome of fixed dose combination of tenofovir, lamivudine and dolutegravir in rural HIV care facility in Nigeria","volume":"11","author":"Ogbuagu","year":"2021","journal-title":"International Journal of Health Sciences and Research"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12879-018-3191-9","article-title":"Uptake of hepatitis B vaccination and its determinants among health care workers in a tertiary health facility in Enugu, South-East, Nigeria","volume":"18","author":"Omotowo","year":"2018","journal-title":"BMC Infectious Diseases"},{"issue":"18","key":"10.1002\/14651858.CD013653.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1097\/QAD.0b013e32832e34b1","article-title":"Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure","volume":"23","author":"Ouyang","year":"2009","journal-title":"AIDS (London, England)"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch13"},{"issue":"6","key":"10.1002\/14651858.CD013653.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/QAD.0000000000001744","article-title":"Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"32","author":"Podany","year":"2018","journal-title":"AIDS (London, England)"},{"issue":"7","key":"10.1002\/14651858.CD013653.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"e68152","DOI":"10.1371\/journal.pone.0068152","article-title":"Suppression of HBV by tenofovir in HBV\/HIV coinfected patients: a systematic review and meta-analysis","volume":"8","author":"Price","year":"2013","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0082|cit82","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2020"},{"issue":"17","key":"10.1002\/14651858.CD013653.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJMoa1701666","article-title":"Birth outcomes for pregnant women with HIV using tenofovir-emtricitabine","volume":"378","author":"Rough","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/cid\/ciu729","article-title":"Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus","volume":"42","author":"Saag","year":"2006","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013653.pub2-BIB0085|cit85","first-page":"226","article-title":"Antenatal transmission of hepatitis B virus in an area of HIV moderate prevalence, Burkina Faso","volume":"102","author":"Sangar\u00e9","year":"2009","journal-title":"Bulletin de la Societe de Pathologie Exotique"},{"issue":"11","key":"10.1002\/14651858.CD013653.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"E1077","DOI":"10.3390\/v11111077","article-title":"HBV infection in HIV-driven immune suppression","volume":"11","author":"Sarmati","year":"2019","journal-title":"Viruses"},{"issue":"35","key":"10.1002\/14651858.CD013653.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD013653.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013653.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/aje\/kwx344","article-title":"Association between risk-of-bias assessments and results of randomized trials in Cochrane Reviews: The ROBES Meta-Epidemiologic Study","volume":"187","author":"Savovi\u0107","year":"2018","journal-title":"American Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD013653.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"408\u201312","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","article-title":"The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold","volume":"154","author":"Seley-Radtke","year":"2018","journal-title":"Antiviral Research"},{"issue":"7","key":"10.1002\/14651858.CD013653.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003510.pub3","article-title":"Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection","author":"Siegfried","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013653.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"e019022","DOI":"10.1136\/bmjopen-2017-019022","article-title":"Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis","volume":"7","author":"Siemieniuk","year":"2017","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0094|cit94","unstructured":"Sterne JA Egger M Chapter 10: Addressing reporting biases. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/1756-0500-4-561","article-title":"Emergence of HBV resistance to lamivudine (3TC) in HIV\/HBV co-infected patients in The Gambia, West Africa","volume":"4","author":"Stewart","year":"2011","journal-title":"BMC Research Notes"},{"issue":"5","key":"10.1002\/14651858.CD013653.pub2-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012069.pub2","article-title":"Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents \u2013 assessment of adverse events in non-randomised studies","author":"Storeb\u00f8","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"40","key":"10.1002\/14651858.CD013653.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"14598","DOI":"10.3748\/wjg.v20.i40.14598","article-title":"Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review","volume":"20","author":"Sun","year":"2014","journal-title":"World Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD013653.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/23744235.2017.1384957","article-title":"Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review","volume":"50","author":"Tavakolpour","year":"2018","journal-title":"Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/s12879-017-2695-z","article-title":"Prevalence of hepatitis B in people living with HIV\/AIDS in Latin America and the Caribbean: a systematic review and meta-analysis","volume":"17","author":"Tengan","year":"2017","journal-title":"BMC Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD013653.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0102|cit102","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User Manual for Trial Sequential Analysis (TSA); 2nd edition. Copenhagen Trial Unit, 2017 Available from ctu.dk\/tsa\/learn-more"},{"issue":"10","key":"10.1002\/14651858.CD013653.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1681\/ASN.2012080857","article-title":"Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?","volume":"24","author":"Tourret","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0104|cit104","unstructured":"TSA - Trial Sequential Analysis Copenhagen Trial Unit 2017"},{"issue":"10","key":"10.1002\/14651858.CD013653.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1517\/17425255.2012.714367","article-title":"Emtricitabine\/tenofovir in the treatment of HIV infection: current PK\/PD evaluation","volume":"8","author":"Uglietti","year":"2012","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"7","key":"10.1002\/14651858.CD013653.pub2-BIB0106|cit106","first-page":"1","article-title":"Correlates and prevalence of human immunodeficiency virus and hepatitis B virus co-infection in pregnancy","volume":"3","author":"Uyoh","year":"2018","journal-title":"International Journal of Advances in Advances in Medical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD013653.pub2-BIB0107|cit107","first-page":"2473","article-title":"Viral quasi species of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine\/adefovir rescue therapy","volume":"17","author":"Wang","year":"2019","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"e0227776","DOI":"10.1371\/journal.pone.0227776","article-title":"Hepatitis B and C virus infection among HIV patients within the public and private healthcare systems in Chile: a cross-sectional serosurvey","volume":"15","author":"Weitzel","year":"2020","journal-title":"PLOS One"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"64\u201375","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in a random-effects meta-analysis","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD013653.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD013653.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2133\/dmpk.DMPK-12-RG-124","article-title":"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19","volume":"28","author":"Xu","year":"2013","journal-title":"Drug Metabolism and Pharmacokinetics"},{"key":"10.1002\/14651858.CD013653.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2016.02.003","article-title":"Management of mother-to-child transmission of hepatitis B virus: propositions and challenges","volume":"77","author":"Yi","year":"2016","journal-title":"Journal of Clinical Virology"},{"issue":"10","key":"10.1002\/14651858.CD013653.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"e172222","DOI":"10.1001\/jamapediatrics.2017.2222","article-title":"Comparative safety of antiretroviral treatment regimens in pregnancy","volume":"171","author":"Zash","year":"2017","journal-title":"JAMA Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD013653.pub2-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013653","article-title":"Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus","author":"Ugwu","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T22:58:00Z","timestamp":1716159480000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013653.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":116,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013653.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}